Safety and radiosensitizing efficacy of sanazole (AK 2123) in oropharyngeal cancers: Randomized controlled double blind clinical trial

Indian Journal of Cancer

Volumn 43, Issue 4, 2006, Pages 151-155

  Ullal, Sheetal D ^a   Shenoy, K K ^a   Pai, M R S M ^a   Chowta, M N ^a   Adiga, S M N ^a   Dinesh, M ^a   Kamath, A ^a   Kotian, M S ^a   Pai, D K ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Oropharyngeal cancer; Radiosensitization; Sanazole

Indexed keywords

EID: 33846228421     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-509X.29419     Document Type: Article

References (14)

1. Mehrotra R, Singh M, Gupta RK, Singh M, Kapoor AK. Trends of prevalence and pathological spectrum of head and neck cancers in North India. Indian J Cancer 2005;42:89-93.
2. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply and metabolic microenvironment of human tumors: A Review. Cancer Res 1989;49:6449-65.
3. Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jorgensen K, Sandberg E, et al. Misonidazole combined with splitcourse radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989;16:1065-8.
4. Eschwege F, Sancho-Garnier H, Chassagne D, Brisgand D, Guerra M, Malaise EP, et al. Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. Int J Radiat Oncol Biol Phys 1997;39:275-81.
5. Lee DJ, Cosmatos D, Marcial VA, Fu KK, Rotman M, Cooper JS, et al. Results of an RTOG Phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995;32:567-76.
6. Shibamoto Y, Sakano K, Kimura R, Nishidai T, Nishimoto S, Ono K, et al. Radiosensitization in vitro and in vivo by 3-nitrotriazoles. Int J Radiat Oncol Biol Phys 1986;12:1063-6.
7. Huilgol NG, Chatterjee N, Mehta AR. An overview of the initial experience with AK 2123 as a hypoxic cell sensitizer with radiation in the treatment of advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1996;34:1121-4.
8. Chaplin DJ, Durand RE, Olive PL. Acute hypoxia in tumor: Implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 1986;12:1279-82.
9. Sugie C, Shibamoto Y, Ito M, Ogino H, Suzuki H, Uto Y, et al. Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo. J Radiat Res 2005;46:453-9.
10. Sakano K, Kimura R, Shibamoto Y, Nishidai T, Nishimoto S, Abe M. A nitroimidazole derivative, AK 2123 as a hypoxic cellsensitizer: Neurotoxicity and pharmacokinetics. Radiosensitization Newslett 1986;5:1-2.
11. Kondakova IV, Tcheredova VV, Zagrebelnaya GV, Cherdyntseva NV, Kagiya TV, Choinzonov EL. Production of nitric oxide by hypoxic radiosensitizer Sanazole. Exp Oncol 2004;26:329-33.
12. Kagiya VT. Pharmacology of AK 2123 by p.o. and i.v. administration in male human being. Radiosensitization Newslett 1990;9:1-2.
13. Huilgol NG, Dobrowsky W, Tatsuzaki H, Chatterjee NA, Kagiya VT, Das K. Sanazole as a sensitizer of hypoxic cells with radical radiation in the treatment of advanced cancer of cervix an Indian experience. Indian J Cancer 2002;39:39-44.
14. Dobrowsky W, Huigol NG, Jayatilake RS, Kizilbash N, Okkan S, Kagiya TV, et al. AK-2123 (Sanazole) as a radiation sensitizer in the treatment of stage iii cancer cervix: Initial results of an IAEA multicentre randomized trial. J Can Res Ther 2005;1:75-8.